MCRB vs. TYRA, GOSS, PROK, DNA, BCAX, SNDL, SEPN, SVRA, MRVI, and ORGO
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Tyra Biosciences (TYRA), Gossamer Bio (GOSS), ProKidney (PROK), Ginkgo Bioworks (DNA), Bicara Therapeutics (BCAX), SNDL (SNDL), Septerna (SEPN), Savara (SVRA), Maravai LifeSciences (MRVI), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.
Seres Therapeutics vs. Its Competitors
Seres Therapeutics (NASDAQ:MCRB) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Seres Therapeutics presently has a consensus target price of $73.67, indicating a potential upside of 319.28%. Tyra Biosciences has a consensus target price of $31.86, indicating a potential upside of 155.47%. Given Seres Therapeutics' higher probable upside, equities analysts clearly believe Seres Therapeutics is more favorable than Tyra Biosciences.
Seres Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Seres Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 15.2% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Tyra Biosciences had 5 more articles in the media than Seres Therapeutics. MarketBeat recorded 8 mentions for Tyra Biosciences and 3 mentions for Seres Therapeutics. Tyra Biosciences' average media sentiment score of 1.22 beat Seres Therapeutics' score of 0.93 indicating that Tyra Biosciences is being referred to more favorably in the news media.
Tyra Biosciences' return on equity of -31.22% beat Seres Therapeutics' return on equity.
Summary
Tyra Biosciences beats Seres Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MCRB) was last updated on 9/12/2025 by MarketBeat.com Staff
Free MCRB Stock Alerts